FDA Guidance Makes Vinpocetine Compliant Despite Ban Proposal – NPA
This article was originally published in The Rose Sheet
NPA CEO Daniel Fabricant says some vinpocetine product marketers don't realize the ingredient's status as an active moiety of a botanical long used in the food supply, a knowledge gap obscures that FDA is using an extra-regulatory procedure to remove vinpocetine.
You may also be interested in...
Agency announces plan in statement by two deputy commissioners warning consumers about safety concerns regarding the semi-synthetic derivative of vincamine, "specifically concerns about the use of this ingredient by women of childbearing age." Recent findings by NIH National Toxicology Program's study with rats and rabbits indicate "vinpocetine may cause a miscarriage or harm fetal development," FDA says.
FDA announces addition of Dietary Supplement Ingredient Advisory List page to its website to identify ingredients it has preliminary determined should be used in dietary supplements. It also publishes warning letters submitted recently to firms marketing supplements containing two ingredients agency has concluded should not be used: eight were warned about using an ingredient identified as "DMHA" and three about using phenibut.
Contract manufacturer Nutritional Engineering was warned on Sept. 29, 2017, about GMP violations and misbranding problems found during an inspection in April and May. Liberty, Texas, own-labeler Carol Bond Health Foods was warned March 9 following a September inspection of its facility and a November review of its website.